Skip to main content

Table 3 Schedule of enrolment, interventions, and assessments

From: Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis

Back to article page

Trials

ISSN: 1745-6215